Treatment of non-small-cell lung cancer after progression on nivolumab or pembrolizumab.

Background Although PD-1 antibodies (PD1 Ab) are the standard of care for advanced non-small-cell lung cancer (ansclc), most patients will progress. We compared survival outcomes for patients with ansclc who received systemic therapy (st) after progression and for those who did not. Additionally, cl...

Descripción completa

Detalles Bibliográficos

Publicado en:	Current Oncology Vol. 27; no. 2; pp. 76 - 83
Autores principales:	Freeman, A. T., Lesperance, M., Wai, E. S., Croteau, N. S., Fiorino, L., Geller, G., Brooks, E. G., Poonja, Z., Fenton, D., Irons, S., Ksienski, D.
Formato:	Journal Article
Publicado:	MDPI Apr2020
Acceso en línea:	Ver este registro en EBSCOhost